1.18
price down icon16.90%   -0.24
after-market Dopo l'orario di chiusura: 1.15 -0.03 -2.54%
loading
Precedente Chiudi:
$1.42
Aprire:
$1.26
Volume 24 ore:
2.15M
Relative Volume:
1.41
Capitalizzazione di mercato:
$7.71M
Reddito:
-
Utile/perdita netta:
$-11.27M
Rapporto P/E:
-0.0551
EPS:
-21.4132
Flusso di cassa netto:
$-9.40M
1 W Prestazione:
-4.84%
1M Prestazione:
+1.62%
6M Prestazione:
-24.36%
1 anno Prestazione:
-80.85%
Intervallo 1D:
Value
$1.18
$1.32
Intervallo di 1 settimana:
Value
$1.18
$2.37
Portata 52W:
Value
$1.00
$6.666

Dermata Therapeutics Inc Stock (DRMA) Company Profile

Name
Nome
Dermata Therapeutics Inc
Name
Telefono
(858)-223-0882
Name
Indirizzo
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-15
Name
Ultimi documenti SEC
Name
DRMA's Discussions on Twitter

Confronta DRMA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DRMA
Dermata Therapeutics Inc
1.18 7.71M 0 -11.27M -9.40M -21.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Dermata Therapeutics Inc Borsa (DRMA) Ultime notizie

pulisher
Mar 28, 2025

Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com newswire

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - StockTitan

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga India

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

XYNGARI shows promise in Phase 3 acne trial - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - StockTitan

Mar 27, 2025
pulisher
Mar 25, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com

Mar 25, 2025
pulisher
Mar 17, 2025

Dermata Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan

Mar 17, 2025
pulisher
Mar 12, 2025

Stocks Rally as US Consumer Prices Cool - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart

Mar 12, 2025
pulisher
Mar 12, 2025

Acne Market on Track for Major Expansion by 2032, According - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 10, 2025

Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World

Mar 10, 2025
pulisher
Mar 04, 2025

Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR

Mar 03, 2025
pulisher
Mar 03, 2025

APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN

Mar 03, 2025
pulisher
Feb 28, 2025

Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga

Feb 28, 2025
pulisher
Feb 25, 2025

DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire

Feb 25, 2025
pulisher
Feb 16, 2025

Dermata Therapeutics announces $2.55M private offering - MSN

Feb 16, 2025
pulisher
Feb 12, 2025

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire

Feb 12, 2025
pulisher
Feb 07, 2025

Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria

Feb 07, 2025
pulisher
Feb 06, 2025

Crown Labs completes acquisition of Revance Therapeutics - Investing.com India

Feb 06, 2025
pulisher
Jan 31, 2025

Dermata to Present on BioPub on January 31, 2025 - ACCESS Newswire

Jan 31, 2025
pulisher
Jan 29, 2025

Dermata Unveils Game-Changing Skin Disease Treatment Progress: CEO Reveals What's Next - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

Acne Vulgaris Market Expected to rise, 2034 | Pelthos - openPR

Jan 29, 2025
pulisher
Jan 28, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 27, 2025

Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Dermata Therapeutics Announces Private Placement of $2.4 Million in Securities SAN DIEGO, CA – Dermata Therapeutics, Inc. (NASDAQ: DRMA) disclosed in a filing on January 21, 2025, that it has entered into a securities purchase agreement for a private - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 24, 2025

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Jan 24, 2025
pulisher
Jan 23, 2025

Dermata Therapeutics secures $2.55 million in private placement - MSN

Jan 23, 2025

Dermata Therapeutics Inc Azioni (DRMA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Capitalizzazione:     |  Volume (24 ore):